Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China
PaperCitations, authors & open-access status
Lorlatinib for Previously Treated ALK-Positive Advanced NSCLC: Primary Efficacy and Safety From a Phase 2 Study in People’s Republic of China is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 34 citations, 2022 year and hybrid oa status.
34
Citations
2022
Year
hybrid
OA Status